Search Results - "Garrison, Dominique A"

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B by Garrison, Dominique A, Jin, Yan, Talebi, Zahra, Hu, Shuiying, Sparreboom, Alex, Baker, Sharyn D, Eisenmann, Eric D

“…Gilteritinib, an FDA-approved tyrosine kinase inhibitor approved for the treatment of relapsed/refractory FLT3-mutated acute myeloid leukemia, is primarily…”
Get full text

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors by Garrison, Dominique A, Talebi, Zahra, Eisenmann, Eric D, Sparreboom, Alex, Baker, Sharyn D

“…Failure to recognize important features of a drug's pharmacokinetic characteristics is a key cause of inappropriate dose and schedule selection, and can lead…”
Get full text

DNA methyltransferase inhibitor exposure–response: Challenges and opportunities by Kagan, Amanda B., Garrison, Dominique A., Anders, Nicole M., Webster, Jonathan A., Baker, Sharyn D., Yegnasubramanian, Srinivasan, Rudek, Michelle A.

“…Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used extensively in the treatment of myelodysplastic syndromes and…”
Get full text

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1 by Uddin, Muhammad Erfan, Garrison, Dominique A, Kim, Kyeongmin, Jin, Yan, Eisenmann, Eric D, Huang, Kevin M, Gibson, Alice A, Hu, Zeping, Sparreboom, Alex, Hu, Shuiying

“…Organic cation transporter 1 (OCT1) is a transporter that regulates the hepatic uptake and subsequent elimination of diverse cationic compounds. Although OCT1…”
Get full text

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia by Uddin, Muhammad Erfan, Eisenmann, Eric D, Li, Yang, Huang, Kevin M, Garrison, Dominique A, Talebi, Zahra, Gibson, Alice A, Jin, Yan, Nepal, Mahesh, Bonilla, Ingrid M, Fu, Qiang, Sun, Xinxin, Millar, Alec, Tarasov, Mikhail, Jay, Christopher E, Cui, Xiaoming, Einolf, Heidi J, Pelis, Ryan M, Smith, Sakima A, Radwański, Przemysław B, Sweet, Douglas H, König, Jörg, Fromm, Martin F, Carnes, Cynthia A, Hu, Shuiying, Sparreboom, Alex

“…Dofetilide is a rapid delayed rectifier potassium current inhibitor widely used to prevent the recurrence of atrial fibrillation and flutter. The clinical use…”
Get full text

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination by Eisenmann, Eric D, Garrison, Dominique A, Talebi, Zahra, Jin, Yan, Silvaroli, Josie A, Kim, Jin-Gyu, Sparreboom, Alex, Savona, Michael R, Mims, Alice S, Baker, Sharyn D

“…Venetoclax, a BCL-2 inhibitor used to treat certain hematological cancers, exhibits low oral bioavailability and high interpatient pharmacokinetic variability…”
Get full text

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method by Talebi, Zahra, Garrison, Dominique A., Eisenmann, Eric D., Parmar, Kalindi, Shapiro, Geoffrey I., Rudek, Michelle A., Sparreboom, Alex, Jin, Yan

“…A rapid, sensitive, and simple UHPLC-MS/MS method for the determination of the PARP inhibitor talazoparib in mouse plasma was developed and validated using…”
Get full text

TP-0903 is active in models of drug-resistant acute myeloid leukemia by Jeon, Jae Yoon, Buelow, Daelynn R, Garrison, Dominique A, Niu, Mingshan, Eisenmann, Eric D, Huang, Kevin M, Zavorka Thomas, Megan E, Weber, Robert H, Whatcott, Clifford J, Warner, Steve L, Orwick, Shelley J, Carmichael, Bridget, Stahl, Emily, Brinton, Lindsey T, Lapalombella, Rosa, Blachly, James S, Hertlein, Erin, Byrd, John C, Bhatnagar, Bhavana, Baker, Sharyn D

“…Effective treatment for AML is challenging due to the presence of clonal heterogeneity and the evolution of polyclonal drug resistance. Here, we report that…”
Get full text

Development, validation, and application of an LC-MS/MS method for the determination of the AXL/FLT3 inhibitor gilteritinib in mouse plasma by Garrison, Dominique A., Jin, Yan, Uddin, Muhammad Erfan, Sparreboom, Alex, Baker, Sharyn D.

“…•An LC-MS/MS method was developed and validated for the quantitative determination of gilteritinib concentrations in mouse plasma.•The developed method has a…”
Get full text

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial by Paller, Channing J., Zahurak, Marianna L., Mandl, Adel, Metri, Nicole A., Lalji, Aliya, Heath, Elisabeth, Kelly, William K., Hoimes, Christopher, Barata, Pedro, Taksey, Jason, Garrison, Dominique A., Patra, Kartick, Milne, Ginger L., Anders, Nicole M., Nauroth, Julie M., Durham, Jennifer N., Marshall, Catherine H., Markowski, Mark C., Eisenberger, Mario A., Antonarakis, Emmanuel S., Carducci, Michael A., Denmeade, Samuel R., Levine, Mark

“…Abstract High-dose intravenous vitamin C (HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical…”
Get full text

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition by Eisenmann, Eric D, Fu, Qiang, Muhowski, Elizabeth M, Jin, Yan, Uddin, Muhammad Erfan, Garrison, Dominique A, Weber, Robert H, Woyach, Jennifer, Byrd, John C, Sparreboom, Alex, Baker, Sharyn D

“…Ibrutinib (Imbruvica; PCI-32765) is an orally administered inhibitor of Bruton's tyrosine kinase that has transformed the treatment of B-cell malignancies…”
Get full text

High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase 2 Trial by Paller, Channing J, Zahurak, Marianna L, Mandl, Adel, Metri, Nicole A, Lalji, Aliya, Heath, Elisabeth, Kelly, William K, Hoimes, Christopher, Barata, Pedro, Taksey, Jason, Garrison, Dominique A, Patra, Kartick, Milne, Ginger L, Anders, Nicole M, Nauroth, Julie M, Durham, Jennifer N, Marshall, Catherine H, Markowski, Mark C, Eisenberger, Mario A, Antonarakis, Emmanuel S, Carducci, Michael A, Denmeade, Samuel R, Levine, Mark

“…High-dose intravenous vitamin C(HDIVC) administered to produce pharmacologic concentrations shows promise in preclinical models and small clinical trials, but…”
Get full text